Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Regulation of selective PPARγ modulators in the differentiation of osteoclasts.

Wu H, Li L, Ma Y, Chen Y, Zhao J, Lu Y, Shen P.

J Cell Biochem. 2013 Sep;114(9):1969-77. doi: 10.1002/jcb.24534.

PMID:
23494891
2.

Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.

Tan Y, Muise ES, Dai H, Raubertas R, Wong KK, Thompson GM, Wood HB, Meinke PT, Lum PY, Thompson JR, Berger JP.

Mol Pharmacol. 2012 Jul;82(1):68-79. doi: 10.1124/mol.111.076679. Epub 2012 Apr 10.

3.

An insulin-sensitizing thiazolidinedione, which minimally activates PPARγ, does not cause bone loss.

Fukunaga T, Zou W, Rohatgi N, Colca JR, Teitelbaum SL.

J Bone Miner Res. 2015 Mar;30(3):481-8. doi: 10.1002/jbmr.2364.

4.

PPAR agonists modulate human osteoclast formation and activity in vitro.

Chan BY, Gartland A, Wilson PJ, Buckley KA, Dillon JP, Fraser WD, Gallagher JA.

Bone. 2007 Jan;40(1):149-59. Epub 2006 Sep 28.

PMID:
17010686
5.

The effects of rosiglitazone on osteoblastic differentiation, osteoclast formation and bone resorption.

Cho ES, Kim MK, Son YO, Lee KS, Park SM, Lee JC.

Mol Cells. 2012 Feb;33(2):173-81. doi: 10.1007/s10059-012-2240-z.

6.

PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss.

Wei W, Wang X, Yang M, Smith LC, Dechow PC, Sonoda J, Evans RM, Wan Y.

Cell Metab. 2010 Jun 9;11(6):503-16. doi: 10.1016/j.cmet.2010.04.015. Erratum in: Cell Metab. 2010 Aug 4;12(2):202. Sonoda, Junichiro [added]; Evans, Ronald M [added].

7.

PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity.

Patel JJ, Butters OR, Arnett TR.

Cell Biochem Funct. 2014 Jun;32(4):368-77. doi: 10.1002/cbf.3025. Epub 2014 Feb 24.

PMID:
24615887
8.

Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway.

Higashi Y, Holder K, Delafontaine P.

J Biol Chem. 2010 Nov 19;285(47):36361-8. doi: 10.1074/jbc.M110.137661. Epub 2010 Sep 15.

9.
10.

Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone.

Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B.

Endocrinology. 2007 Jun;148(6):2669-80. Epub 2007 Mar 1.

11.

[Effect of pioglitazone on receptor activator of nuclear factor-kappa B expression in osteoclast from RAW264.7 cells].

Jiang M, Lü S, Wu L, Liu J, Cheng P, Ding GX.

Zhonghua Yi Xue Za Zhi. 2010 Aug 24;90(32):2282-5. Chinese.

PMID:
21029677
12.

Activation of peroxisome proliferator-activated receptor gamma inhibits TNF-alpha-mediated osteoclast differentiation in human peripheral monocytes in part via suppression of monocyte chemoattractant protein-1 expression.

Hounoki H, Sugiyama E, Mohamed SG, Shinoda K, Taki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Miyahara T.

Bone. 2008 Apr;42(4):765-74. doi: 10.1016/j.bone.2007.11.016. Epub 2007 Dec 15.

PMID:
18242157
13.

Water extract of Spatholobus suberectus inhibits osteoclast differentiation and bone resorption.

Ha H, Shim KS, An H, Kim T, Ma JY.

BMC Complement Altern Med. 2013 May 21;13:112. doi: 10.1186/1472-6882-13-112.

14.

Liver X receptor activation inhibits osteoclastogenesis by suppressing NF-κB activity and c-Fos induction and prevents inflammatory bone loss in mice.

Kim HJ, Yoon KA, Yoon HJ, Hong JM, Lee MJ, Lee IK, Kim SY.

J Leukoc Biol. 2013 Jul;94(1):99-107. doi: 10.1189/jlb.1112601. Epub 2013 May 8.

15.

PPAR gamma: ally and foe in bone metabolism.

Wahli W.

Cell Metab. 2008 Mar;7(3):188-90. doi: 10.1016/j.cmet.2008.02.005.

16.

Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.

Liu W, Lau F, Liu K, Wood HB, Zhou G, Chen Y, Li Y, Akiyama TE, Castriota G, Einstein M, Wang C, McCann ME, Doebber TW, Wu M, Chang CH, McNamara L, McKeever B, Mosley RT, Berger JP, Meinke PT.

J Med Chem. 2011 Dec 22;54(24):8541-54. doi: 10.1021/jm201061j. Epub 2011 Nov 28.

PMID:
22070604
17.

A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways.

Park JY, Bae MA, Cheon HG, Kim SS, Hong JM, Kim TH, Choi JY, Kim SH, Lim J, Choi CH, Shin HI, Kim SY, Park EK.

Biochem Biophys Res Commun. 2009 Jan 16;378(3):645-9. doi: 10.1016/j.bbrc.2008.11.115. Epub 2008 Dec 4.

PMID:
19059209
18.

Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice.

Li M, Pan LC, Simmons HA, Li Y, Healy DR, Robinson BS, Ke HZ, Brown TA.

Bone. 2006 Oct;39(4):796-806. Epub 2006 Jun 8.

PMID:
16759917
19.

Inhibition of osteoclast differentiation and bone resorption by a novel lysophosphatidylcholine derivative, SCOH.

Kwak HB, Lee SW, Li YJ, Kim YA, Han SY, Jhon GJ, Kim HH, Lee ZH.

Biochem Pharmacol. 2004 Apr 1;67(7):1239-48.

PMID:
15013839
20.

Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.

Kim MH, Ryu SY, Choi JS, Min YK, Kim SH.

J Cell Physiol. 2009 Dec;221(3):618-28. doi: 10.1002/jcp.21892.

PMID:
19653230
Items per page

Supplemental Content

Write to the Help Desk